1. (Amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein said antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent, respectively; and (b) a pharmaceutically acceptable carrier.

7. (Amended) The method of claim 1, wherein the cytostatic or cytotoxic effect is exhibited upon performing a method comprising:

(a) contacting a culture of the Hodgkin's Disease cell line with the antibody, said culture being of about 5,000 cells in a culture area of about 0.33 cm^2, said contacting being for a period of 72 hours;

(b) exposing the culture to 0.5 μCi of ^{3}H-thymidine during the final 8 hours of said 72-hour period; and

(c) measuring the incorporation of ^{3}H-thymidine into cells of the culture,

wherein the antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced ^{3}H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody.

8. (Amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of a protein, which protein (a) competes for binding to CD30 with monoclonal antibody AC10 or HeFi-1, and (b) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, which amount is effective for the treatment of Hodgkin's Disease.

11. (Amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of a protein, which protein (a) comprises an amino acid sequence that has at least 95% identity to SEQ ID NO:2 or SEQ ID NO:10, and (b) immunospecifically binds CD30, which amount is effective for the treatment of Hodgkin's Disease.

13. (Amended) The method of any one of claims 8 or 11, wherein the protein is a human, humanized or chimeric antibody.

14. (Amended) The method of any one of claims 8 or 11, further comprising administering chemotherapy to said subject.

Q4

15. (Amended) The method of any one of claims 8 or 11, wherein the protein is conjugated to a cytotoxic agent.

16. (Amended) The method of any one of claims 8 or 11, wherein the protein is a fusion protein comprising the amino acid sequence of a second protein.

19. (Amended) The method of any one of claims 8 or 11, wherein the cytostatic or cytotoxic effect is exhibited upon performing a method comprising:

(a) contacting a culture of the Hodgkin's Disease cell line with the protein, said culture being of about 5,000 cells in a culture area of about 0.33 cm^2, said contacting being for a period of 72 hours;

Q5

(b) exposing the culture to 0.5 μCi of ^{3}H-thymidine during the final 8 hours of said 72-hour period; and

(c) measuring the incorporation of ^{3}H-thymidine into cells of the culture,

wherein the protein has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced ^{3}H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the protein.

REMARKS

Claims 1-8, 11 and 13-19 are under consideration. Claims 9, 10, 12 and 20-52 have been canceled without prejudice as drawn to non-elected inventions. Applicants reserve the right to pursue the subject matter of the canceled claims in one or more related applications. Claims 1, 7, 8, 11, 13-16 and 19 have been amended to more particularly point out and distinctly claim that which Applicants regard as the invention. In particular, claim 1 has been amended to indicate that the claim is directed to the treatment of Hodgkin's Disease